SCHEDULE: Venrock Healthcare Discloses 4.2% Stake in ORIC Pharma
Schedule 13G/A (Beneficial Ownership Report)
Venrock Healthcare Capital Partners and affiliates report a 4.2% beneficial ownership stake in ORIC Pharmaceuticals, Inc.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. collectively hold 4,319,765 shares of ORIC Pharmaceuticals, Inc.
- The reported holdings represent 4.2% of the total outstanding common stock of the issuer.
- The filing confirms that the shares are held for investment purposes and not to influence or change control of the company.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional interest without signaling immediate strategic shifts or activist intent.
Positives
- Institutional backing from a specialized healthcare investment firm indicates long-term confidence in the company's sector positioning.
Negatives
- The reporting group's ownership stake is below the 5% threshold typically associated with significant activist influence.
Risks
- Market volatility affecting the valuation of biotechnology holdings.
- Regulatory and clinical trial risks inherent to the pharmaceutical industry.
Future Outlook
The reporting persons state that the securities were not acquired for the purpose of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that this filing reflects standard institutional portfolio reporting for biotechnology firms, where specialized venture capital and healthcare funds maintain significant but non-controlling positions in clinical-stage companies.
Comparison to Industry Standards
- The 4.2% stake is consistent with typical minority positions held by venture capital firms in mid-cap biotech companies.
- The filing follows standard SEC disclosure requirements for institutional investors under Rule 13d.
Stakeholder Impact
- Shareholders may view the continued presence of Venrock as a sign of institutional stability.
Next Steps
- Continued monitoring of future 13G or 13D filings if the reporting group's ownership crosses the 5% threshold.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of event requiring the filing of this statement. |
| 05/04/2026 | Date of the Issuer's Quarterly Report on Form 10-Q used for share count reference. |
| 05/15/2026 | Date of the filing of this Schedule 13G/A. |
Keywords
ORIC Pharmaceuticals, Venrock Healthcare, Schedule 13G, Biotechnology, Institutional Ownership, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.